Publications by authors named "Nisa Desai"
Article Synopsis
- Patients who receive organ transplants often need immunosuppressive medications, and this study aimed to explore the safety of biologic therapies like infliximab and adalimumab for treating inflammatory bowel disease (IBD) in these patients.
- Researchers analyzed 16 studies involving 163 solid organ transplant recipients to assess outcomes related to infections, complications, and therapy discontinuation.
- The study found infection rates of approximately 20.09 per 100 person-years, with serious infections at 17.39 per 100 person-years, but reported no deaths or significant issues related to the use of biologic therapies.
Ipilimumab is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 approved for the treatment of non-small-cell lung cancer (NSCLC) and other malignancies. Despite a high prevalence of other immune-related adverse events (irAEs), checkpoint inhibitor (CPI)-related nephrotoxicity has been reported less frequently. In this clinical case report, we describe the evaluation of a 70-year-old female with stage IV NSCLC who presented with nephrotic range proteinuria 4 weeks after receiving her first cycle of ipilimumab.
View Article and Find Full Text PDFHispanics are the largest racial/ethnic minority group in the United States, and they experience a substantial burden of kidney disease. Although the prevalence of chronic kidney disease (CKD) is similar or slightly lower in Hispanics than non-Hispanic whites, the age- and sex-adjusted prevalence rate of end-stage renal disease is almost 50% higher in Hispanics compared with non-Hispanic whites. This has been attributed in part to faster CKD progression among Hispanics.
View Article and Find Full Text PDF